Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. (Q43031861)
Jump to navigation
Jump to search
scientific article published on 24 February 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. |
scientific article published on 24 February 2011 |
Statements
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study (English)
Patrick Marcellin
Nicole Forestier
Dominique Larrey
Alain Patat
Patrick Smith
Williamson Bradford
Steven Porter
Lawrence Blatt
Scott D Seiwert
24 February 2011